New England Journal of Medicine· 2017Q1

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Jeffrey I. Weitz, Anthonie W.A. Lensing, Martin H. Prins, Rupert Bauersachs et al.

771citations
Q1SCImago
2017year

Short summary

Rivaroxaban (20 mg or 10 mg daily) significantly reduced recurrent venous thromboembolism by 66-74% compared to aspirin (100 mg daily) in patients needing extended treatment, with similar major bleeding rates.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Internal Medicine

Internal MedicineMedicine